Pharmacokinetic aspects of retinal drug delivery
Drug delivery to the posterior eye segment is an important challenge in ophthalmology, because many diseases affect the retina and choroid leading to impaired vision or blindness. Currently, intravitreal injections are the method of choice to administer drugs to the retina, but this approach is appl...
Gespeichert in:
Veröffentlicht in: | Progress in retinal and eye research 2017-03, Vol.57, p.134-185 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 185 |
---|---|
container_issue | |
container_start_page | 134 |
container_title | Progress in retinal and eye research |
container_volume | 57 |
creator | del Amo, Eva M. Rimpelä, Anna-Kaisa Heikkinen, Emma Kari, Otto K. Ramsay, Eva Lajunen, Tatu Schmitt, Mechthild Pelkonen, Laura Bhattacharya, Madhushree Richardson, Dominique Subrizi, Astrid Turunen, Tiina Reinisalo, Mika Itkonen, Jaakko Toropainen, Elisa Casteleijn, Marco Kidron, Heidi Antopolsky, Maxim Vellonen, Kati-Sisko Ruponen, Marika Urtti, Arto |
description | Drug delivery to the posterior eye segment is an important challenge in ophthalmology, because many diseases affect the retina and choroid leading to impaired vision or blindness. Currently, intravitreal injections are the method of choice to administer drugs to the retina, but this approach is applicable only in selected cases (e.g. anti-VEGF antibodies and soluble receptors). There are two basic approaches that can be adopted to improve retinal drug delivery: prolonged and/or retina targeted delivery of intravitreal drugs and use of other routes of drug administration, such as periocular, suprachoroidal, sub-retinal, systemic, or topical. Properties of the administration route, drug and delivery system determine the efficacy and safety of these approaches. Pharmacokinetic and pharmacodynamic factors determine the required dosing rates and doses that are needed for drug action. In addition, tolerability factors limit the use of many materials in ocular drug delivery. This review article provides a critical discussion of retinal drug delivery, particularly from the pharmacokinetic point of view. This article does not include an extensive review of drug delivery technologies, because they have already been reviewed several times recently. Instead, we aim to provide a systematic and quantitative view on the pharmacokinetic factors in drug delivery to the posterior eye segment. This review is based on the literature and unpublished data from the authors' laboratory. |
doi_str_mv | 10.1016/j.preteyeres.2016.12.001 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1853742143</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1350946216300635</els_id><sourcerecordid>1853742143</sourcerecordid><originalsourceid>FETCH-LOGICAL-c490t-2391ccf38fedb29fb09a6af93c1f3b8fb088b0d314da2889ea71f8c7706e3e2e3</originalsourceid><addsrcrecordid>eNqFkMlOwzAQhi0EoqXwCihHLgljO4tzhIpNqgQHOFuOMwaXbNhJpb49rlrgiDTSLPpnfs1HSEQhoUDz63UyOBxxiw59wsIkoSwBoEdkTkXBY5rz7DjUPIO4THM2I2ferwEghzI7JTMmIATQOYGXD-VapftP2-FodaT8gHr0UW-iYGE71US1m96jGhu7Qbc9JydGNR4vDnlB3u7vXpeP8er54Wl5s4p1WsIYM15SrQ0XBuuKlaaCUuXKlFxTwysReiEqqDlNa8WEKFEV1AhdFJAjR4Z8Qa72dwfXf03oR9lar7FpVIf95CUVGS9SRlMepGIv1a733qGRg7OtcltJQe54ybX84yV3vCRlMvwfVi8PLlPVYv27-AMoCG73Agy_biw66bXFTmNtXeAk697-7_INmL6BnA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1853742143</pqid></control><display><type>article</type><title>Pharmacokinetic aspects of retinal drug delivery</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>del Amo, Eva M. ; Rimpelä, Anna-Kaisa ; Heikkinen, Emma ; Kari, Otto K. ; Ramsay, Eva ; Lajunen, Tatu ; Schmitt, Mechthild ; Pelkonen, Laura ; Bhattacharya, Madhushree ; Richardson, Dominique ; Subrizi, Astrid ; Turunen, Tiina ; Reinisalo, Mika ; Itkonen, Jaakko ; Toropainen, Elisa ; Casteleijn, Marco ; Kidron, Heidi ; Antopolsky, Maxim ; Vellonen, Kati-Sisko ; Ruponen, Marika ; Urtti, Arto</creator><creatorcontrib>del Amo, Eva M. ; Rimpelä, Anna-Kaisa ; Heikkinen, Emma ; Kari, Otto K. ; Ramsay, Eva ; Lajunen, Tatu ; Schmitt, Mechthild ; Pelkonen, Laura ; Bhattacharya, Madhushree ; Richardson, Dominique ; Subrizi, Astrid ; Turunen, Tiina ; Reinisalo, Mika ; Itkonen, Jaakko ; Toropainen, Elisa ; Casteleijn, Marco ; Kidron, Heidi ; Antopolsky, Maxim ; Vellonen, Kati-Sisko ; Ruponen, Marika ; Urtti, Arto</creatorcontrib><description>Drug delivery to the posterior eye segment is an important challenge in ophthalmology, because many diseases affect the retina and choroid leading to impaired vision or blindness. Currently, intravitreal injections are the method of choice to administer drugs to the retina, but this approach is applicable only in selected cases (e.g. anti-VEGF antibodies and soluble receptors). There are two basic approaches that can be adopted to improve retinal drug delivery: prolonged and/or retina targeted delivery of intravitreal drugs and use of other routes of drug administration, such as periocular, suprachoroidal, sub-retinal, systemic, or topical. Properties of the administration route, drug and delivery system determine the efficacy and safety of these approaches. Pharmacokinetic and pharmacodynamic factors determine the required dosing rates and doses that are needed for drug action. In addition, tolerability factors limit the use of many materials in ocular drug delivery. This review article provides a critical discussion of retinal drug delivery, particularly from the pharmacokinetic point of view. This article does not include an extensive review of drug delivery technologies, because they have already been reviewed several times recently. Instead, we aim to provide a systematic and quantitative view on the pharmacokinetic factors in drug delivery to the posterior eye segment. This review is based on the literature and unpublished data from the authors' laboratory.</description><identifier>ISSN: 1350-9462</identifier><identifier>EISSN: 1873-1635</identifier><identifier>DOI: 10.1016/j.preteyeres.2016.12.001</identifier><identifier>PMID: 28028001</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Angiogenesis Inhibitors - administration & dosage ; Angiogenesis Inhibitors - pharmacokinetics ; Animals ; Choroid ; Clearance ; Distribution ; Drug Delivery Systems ; Humans ; Intravitreal ; Intravitreal Injections ; Pharmacokinetic modeling ; Retina ; Retina - metabolism ; Retinal Diseases - drug therapy ; Retinal Diseases - metabolism ; Sub-conjunctival ; Suprachoroidal ; Tissue Distribution ; Topical ; Transport ; Vitreous</subject><ispartof>Progress in retinal and eye research, 2017-03, Vol.57, p.134-185</ispartof><rights>2017 The Authors</rights><rights>Copyright © 2017 The Authors. Published by Elsevier Ltd.. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c490t-2391ccf38fedb29fb09a6af93c1f3b8fb088b0d314da2889ea71f8c7706e3e2e3</citedby><cites>FETCH-LOGICAL-c490t-2391ccf38fedb29fb09a6af93c1f3b8fb088b0d314da2889ea71f8c7706e3e2e3</cites><orcidid>0000-0003-4093-3465 ; 0000-0002-1201-5010 ; 0000-0001-8549-7092 ; 0000-0002-4380-4127 ; 0000-0001-5923-7289 ; 0000-0001-6617-1513 ; 0000-0002-6090-1156 ; 0000-0003-2109-3632 ; 0000-0001-6234-9193</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1350946216300635$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28028001$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>del Amo, Eva M.</creatorcontrib><creatorcontrib>Rimpelä, Anna-Kaisa</creatorcontrib><creatorcontrib>Heikkinen, Emma</creatorcontrib><creatorcontrib>Kari, Otto K.</creatorcontrib><creatorcontrib>Ramsay, Eva</creatorcontrib><creatorcontrib>Lajunen, Tatu</creatorcontrib><creatorcontrib>Schmitt, Mechthild</creatorcontrib><creatorcontrib>Pelkonen, Laura</creatorcontrib><creatorcontrib>Bhattacharya, Madhushree</creatorcontrib><creatorcontrib>Richardson, Dominique</creatorcontrib><creatorcontrib>Subrizi, Astrid</creatorcontrib><creatorcontrib>Turunen, Tiina</creatorcontrib><creatorcontrib>Reinisalo, Mika</creatorcontrib><creatorcontrib>Itkonen, Jaakko</creatorcontrib><creatorcontrib>Toropainen, Elisa</creatorcontrib><creatorcontrib>Casteleijn, Marco</creatorcontrib><creatorcontrib>Kidron, Heidi</creatorcontrib><creatorcontrib>Antopolsky, Maxim</creatorcontrib><creatorcontrib>Vellonen, Kati-Sisko</creatorcontrib><creatorcontrib>Ruponen, Marika</creatorcontrib><creatorcontrib>Urtti, Arto</creatorcontrib><title>Pharmacokinetic aspects of retinal drug delivery</title><title>Progress in retinal and eye research</title><addtitle>Prog Retin Eye Res</addtitle><description>Drug delivery to the posterior eye segment is an important challenge in ophthalmology, because many diseases affect the retina and choroid leading to impaired vision or blindness. Currently, intravitreal injections are the method of choice to administer drugs to the retina, but this approach is applicable only in selected cases (e.g. anti-VEGF antibodies and soluble receptors). There are two basic approaches that can be adopted to improve retinal drug delivery: prolonged and/or retina targeted delivery of intravitreal drugs and use of other routes of drug administration, such as periocular, suprachoroidal, sub-retinal, systemic, or topical. Properties of the administration route, drug and delivery system determine the efficacy and safety of these approaches. Pharmacokinetic and pharmacodynamic factors determine the required dosing rates and doses that are needed for drug action. In addition, tolerability factors limit the use of many materials in ocular drug delivery. This review article provides a critical discussion of retinal drug delivery, particularly from the pharmacokinetic point of view. This article does not include an extensive review of drug delivery technologies, because they have already been reviewed several times recently. Instead, we aim to provide a systematic and quantitative view on the pharmacokinetic factors in drug delivery to the posterior eye segment. This review is based on the literature and unpublished data from the authors' laboratory.</description><subject>Angiogenesis Inhibitors - administration & dosage</subject><subject>Angiogenesis Inhibitors - pharmacokinetics</subject><subject>Animals</subject><subject>Choroid</subject><subject>Clearance</subject><subject>Distribution</subject><subject>Drug Delivery Systems</subject><subject>Humans</subject><subject>Intravitreal</subject><subject>Intravitreal Injections</subject><subject>Pharmacokinetic modeling</subject><subject>Retina</subject><subject>Retina - metabolism</subject><subject>Retinal Diseases - drug therapy</subject><subject>Retinal Diseases - metabolism</subject><subject>Sub-conjunctival</subject><subject>Suprachoroidal</subject><subject>Tissue Distribution</subject><subject>Topical</subject><subject>Transport</subject><subject>Vitreous</subject><issn>1350-9462</issn><issn>1873-1635</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkMlOwzAQhi0EoqXwCihHLgljO4tzhIpNqgQHOFuOMwaXbNhJpb49rlrgiDTSLPpnfs1HSEQhoUDz63UyOBxxiw59wsIkoSwBoEdkTkXBY5rz7DjUPIO4THM2I2ferwEghzI7JTMmIATQOYGXD-VapftP2-FodaT8gHr0UW-iYGE71US1m96jGhu7Qbc9JydGNR4vDnlB3u7vXpeP8er54Wl5s4p1WsIYM15SrQ0XBuuKlaaCUuXKlFxTwysReiEqqDlNa8WEKFEV1AhdFJAjR4Z8Qa72dwfXf03oR9lar7FpVIf95CUVGS9SRlMepGIv1a733qGRg7OtcltJQe54ybX84yV3vCRlMvwfVi8PLlPVYv27-AMoCG73Agy_biw66bXFTmNtXeAk697-7_INmL6BnA</recordid><startdate>201703</startdate><enddate>201703</enddate><creator>del Amo, Eva M.</creator><creator>Rimpelä, Anna-Kaisa</creator><creator>Heikkinen, Emma</creator><creator>Kari, Otto K.</creator><creator>Ramsay, Eva</creator><creator>Lajunen, Tatu</creator><creator>Schmitt, Mechthild</creator><creator>Pelkonen, Laura</creator><creator>Bhattacharya, Madhushree</creator><creator>Richardson, Dominique</creator><creator>Subrizi, Astrid</creator><creator>Turunen, Tiina</creator><creator>Reinisalo, Mika</creator><creator>Itkonen, Jaakko</creator><creator>Toropainen, Elisa</creator><creator>Casteleijn, Marco</creator><creator>Kidron, Heidi</creator><creator>Antopolsky, Maxim</creator><creator>Vellonen, Kati-Sisko</creator><creator>Ruponen, Marika</creator><creator>Urtti, Arto</creator><general>Elsevier Ltd</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-4093-3465</orcidid><orcidid>https://orcid.org/0000-0002-1201-5010</orcidid><orcidid>https://orcid.org/0000-0001-8549-7092</orcidid><orcidid>https://orcid.org/0000-0002-4380-4127</orcidid><orcidid>https://orcid.org/0000-0001-5923-7289</orcidid><orcidid>https://orcid.org/0000-0001-6617-1513</orcidid><orcidid>https://orcid.org/0000-0002-6090-1156</orcidid><orcidid>https://orcid.org/0000-0003-2109-3632</orcidid><orcidid>https://orcid.org/0000-0001-6234-9193</orcidid></search><sort><creationdate>201703</creationdate><title>Pharmacokinetic aspects of retinal drug delivery</title><author>del Amo, Eva M. ; Rimpelä, Anna-Kaisa ; Heikkinen, Emma ; Kari, Otto K. ; Ramsay, Eva ; Lajunen, Tatu ; Schmitt, Mechthild ; Pelkonen, Laura ; Bhattacharya, Madhushree ; Richardson, Dominique ; Subrizi, Astrid ; Turunen, Tiina ; Reinisalo, Mika ; Itkonen, Jaakko ; Toropainen, Elisa ; Casteleijn, Marco ; Kidron, Heidi ; Antopolsky, Maxim ; Vellonen, Kati-Sisko ; Ruponen, Marika ; Urtti, Arto</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c490t-2391ccf38fedb29fb09a6af93c1f3b8fb088b0d314da2889ea71f8c7706e3e2e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Angiogenesis Inhibitors - administration & dosage</topic><topic>Angiogenesis Inhibitors - pharmacokinetics</topic><topic>Animals</topic><topic>Choroid</topic><topic>Clearance</topic><topic>Distribution</topic><topic>Drug Delivery Systems</topic><topic>Humans</topic><topic>Intravitreal</topic><topic>Intravitreal Injections</topic><topic>Pharmacokinetic modeling</topic><topic>Retina</topic><topic>Retina - metabolism</topic><topic>Retinal Diseases - drug therapy</topic><topic>Retinal Diseases - metabolism</topic><topic>Sub-conjunctival</topic><topic>Suprachoroidal</topic><topic>Tissue Distribution</topic><topic>Topical</topic><topic>Transport</topic><topic>Vitreous</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>del Amo, Eva M.</creatorcontrib><creatorcontrib>Rimpelä, Anna-Kaisa</creatorcontrib><creatorcontrib>Heikkinen, Emma</creatorcontrib><creatorcontrib>Kari, Otto K.</creatorcontrib><creatorcontrib>Ramsay, Eva</creatorcontrib><creatorcontrib>Lajunen, Tatu</creatorcontrib><creatorcontrib>Schmitt, Mechthild</creatorcontrib><creatorcontrib>Pelkonen, Laura</creatorcontrib><creatorcontrib>Bhattacharya, Madhushree</creatorcontrib><creatorcontrib>Richardson, Dominique</creatorcontrib><creatorcontrib>Subrizi, Astrid</creatorcontrib><creatorcontrib>Turunen, Tiina</creatorcontrib><creatorcontrib>Reinisalo, Mika</creatorcontrib><creatorcontrib>Itkonen, Jaakko</creatorcontrib><creatorcontrib>Toropainen, Elisa</creatorcontrib><creatorcontrib>Casteleijn, Marco</creatorcontrib><creatorcontrib>Kidron, Heidi</creatorcontrib><creatorcontrib>Antopolsky, Maxim</creatorcontrib><creatorcontrib>Vellonen, Kati-Sisko</creatorcontrib><creatorcontrib>Ruponen, Marika</creatorcontrib><creatorcontrib>Urtti, Arto</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Progress in retinal and eye research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>del Amo, Eva M.</au><au>Rimpelä, Anna-Kaisa</au><au>Heikkinen, Emma</au><au>Kari, Otto K.</au><au>Ramsay, Eva</au><au>Lajunen, Tatu</au><au>Schmitt, Mechthild</au><au>Pelkonen, Laura</au><au>Bhattacharya, Madhushree</au><au>Richardson, Dominique</au><au>Subrizi, Astrid</au><au>Turunen, Tiina</au><au>Reinisalo, Mika</au><au>Itkonen, Jaakko</au><au>Toropainen, Elisa</au><au>Casteleijn, Marco</au><au>Kidron, Heidi</au><au>Antopolsky, Maxim</au><au>Vellonen, Kati-Sisko</au><au>Ruponen, Marika</au><au>Urtti, Arto</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pharmacokinetic aspects of retinal drug delivery</atitle><jtitle>Progress in retinal and eye research</jtitle><addtitle>Prog Retin Eye Res</addtitle><date>2017-03</date><risdate>2017</risdate><volume>57</volume><spage>134</spage><epage>185</epage><pages>134-185</pages><issn>1350-9462</issn><eissn>1873-1635</eissn><abstract>Drug delivery to the posterior eye segment is an important challenge in ophthalmology, because many diseases affect the retina and choroid leading to impaired vision or blindness. Currently, intravitreal injections are the method of choice to administer drugs to the retina, but this approach is applicable only in selected cases (e.g. anti-VEGF antibodies and soluble receptors). There are two basic approaches that can be adopted to improve retinal drug delivery: prolonged and/or retina targeted delivery of intravitreal drugs and use of other routes of drug administration, such as periocular, suprachoroidal, sub-retinal, systemic, or topical. Properties of the administration route, drug and delivery system determine the efficacy and safety of these approaches. Pharmacokinetic and pharmacodynamic factors determine the required dosing rates and doses that are needed for drug action. In addition, tolerability factors limit the use of many materials in ocular drug delivery. This review article provides a critical discussion of retinal drug delivery, particularly from the pharmacokinetic point of view. This article does not include an extensive review of drug delivery technologies, because they have already been reviewed several times recently. Instead, we aim to provide a systematic and quantitative view on the pharmacokinetic factors in drug delivery to the posterior eye segment. This review is based on the literature and unpublished data from the authors' laboratory.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>28028001</pmid><doi>10.1016/j.preteyeres.2016.12.001</doi><tpages>52</tpages><orcidid>https://orcid.org/0000-0003-4093-3465</orcidid><orcidid>https://orcid.org/0000-0002-1201-5010</orcidid><orcidid>https://orcid.org/0000-0001-8549-7092</orcidid><orcidid>https://orcid.org/0000-0002-4380-4127</orcidid><orcidid>https://orcid.org/0000-0001-5923-7289</orcidid><orcidid>https://orcid.org/0000-0001-6617-1513</orcidid><orcidid>https://orcid.org/0000-0002-6090-1156</orcidid><orcidid>https://orcid.org/0000-0003-2109-3632</orcidid><orcidid>https://orcid.org/0000-0001-6234-9193</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1350-9462 |
ispartof | Progress in retinal and eye research, 2017-03, Vol.57, p.134-185 |
issn | 1350-9462 1873-1635 |
language | eng |
recordid | cdi_proquest_miscellaneous_1853742143 |
source | MEDLINE; Elsevier ScienceDirect Journals |
subjects | Angiogenesis Inhibitors - administration & dosage Angiogenesis Inhibitors - pharmacokinetics Animals Choroid Clearance Distribution Drug Delivery Systems Humans Intravitreal Intravitreal Injections Pharmacokinetic modeling Retina Retina - metabolism Retinal Diseases - drug therapy Retinal Diseases - metabolism Sub-conjunctival Suprachoroidal Tissue Distribution Topical Transport Vitreous |
title | Pharmacokinetic aspects of retinal drug delivery |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T14%3A43%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pharmacokinetic%20aspects%20of%20retinal%20drug%20delivery&rft.jtitle=Progress%20in%20retinal%20and%20eye%20research&rft.au=del%20Amo,%20Eva%20M.&rft.date=2017-03&rft.volume=57&rft.spage=134&rft.epage=185&rft.pages=134-185&rft.issn=1350-9462&rft.eissn=1873-1635&rft_id=info:doi/10.1016/j.preteyeres.2016.12.001&rft_dat=%3Cproquest_cross%3E1853742143%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1853742143&rft_id=info:pmid/28028001&rft_els_id=S1350946216300635&rfr_iscdi=true |